Last updated 8 days ago
A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma
531 patients around the world
Available in Argentina, United States, Mexico, Brazil
Eli Lilly and Company
24Research sites
531Patients around the world
This study is for people with
Asthma
Requirements for the patient
To 75 Years
All Gender
Medical requirements
- Physician-diagnosed asthma who have received a physician-prescribed asthma controller medication for at least 12 months prior to screening visit.Participants must have an asthma control questionnaire-6 (ACQ-6) score of ≥1.5 on 2 out of 3 visits before randomization.History of 1 severe asthma exacerbation that led to systemic glucocorticoid treatment in the last 12 months prior to screening visit.
- Participants are excluded from the study if any of the following criteria apply.An established diagnosis of occupational asthma.Known pre-existing, clinically important lung condition other than asthma, including but not limited to.Chronic respiratory infection.Bronchiectasis.Pulmonary fibrosis.Allergic bronchopulmonary aspergillosis.Emphysema.Chronic bronchitis.Eosinophilic granulomatosis with polyangiitis.Chronic obstructive pulmonary disease.Other mimics of asthma, that is, vocal cord dysfunction.Have a current or recent acute, active infection for at least 30 days before screening visit and up to the randomization visit.
Sites
Centro de Investigaciones Metabólicas (CINME) S.A. - CABA, Buenos Aires
IDIM - sede centro - CABA
Centro de Investigaciones Clínicas Baigorria
Instituto de Investigaciones Clínicas Mar del Plata
Servicio de Investigación de Patologías Alérgicas del Instituto ABC
Instituto Médico Río Cuarto
Fundación Respirar
Consultorios Médicos del Buen Ayre
Ibamédica
Instituto de Asma, Alergia y Enfermedades Respiratorias - I.A.A.E.R.
SponsorEli Lilly and Company
Study typeInterventional
Conditions
Asthma
Requirements
To 75 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT07219173
